BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32898684)

  • 1. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis.
    Tattevin P; Dinh A; Ghout I; Mouton W; Verdier MC; Laurent F; Lemaitre F; Gatin L; Saleh-Mghir A; Crémieux AC
    Int J Antimicrob Agents; 2020 Nov; 56(5):106152. PubMed ID: 32898684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin-containing cement spacer for treatment of experimental carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection.
    Gatin L; Mghir AS; Mouton W; Laurent F; Ghout I; Rioux-Leclercq N; Tattevin P; Verdier MC; Cremieux AC
    Int J Antimicrob Agents; 2019 Oct; 54(4):456-462. PubMed ID: 31319190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
    Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
    Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency Determination of Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) Isolated from hospitals in Isfahan of Iran and Evaluation of Synergistic Effect of Colistin and Meropenem on them.
    Gheitani L; Fazeli H; Moghim S; Nasr Isfahani B
    Cell Mol Biol (Noisy-le-grand); 2018 Jan; 64(1):70-74. PubMed ID: 29412797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
    Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 20. Captopril potentiated meropenem activity against MBL-producing carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study.
    Zhao D; Li H; Yue C; Sun K; Dai Y; Zhang H; Liu Y; Gao Y; Li J
    J Inorg Biochem; 2021 May; 218():111381. PubMed ID: 33647540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.